From tall to short: The role of TGFβ Signaling in growth and its disorders

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 160 C, Issue 3, 2012, Pages 145-153

  Le Goff, Carine ^a   Cormier Daire, Vale rie ^a  

^a IMAGINE INSTITUTE   (France)

Author keywords

Marfan syndrome; Transforming growth factor

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; COMPLEX FORMATION; GENETIC TRANSCRIPTION; MARFAN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BODY HEIGHT; BONE DISEASES, DEVELOPMENTAL; GROWTH AND DEVELOPMENT; HUMANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864053461     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.31337     Document Type: Article

References (46)

1. Allali S, Le Goff C, Pressac-Diebold I, Pfennig G, Mahaut C, Dagoneau N, Alanay Y, Brady AF, Crow YJ, Devriendt K, Drouin-Garraud V, Flori E, Geneviève D, Hennekam RC, Hurst J, Krakow D, Le Merrer M, Lichtenbelt KD, Lynch SA, Lyonnet S, MacDermot K, Mansour S, Megarbane; A, Santos HG, Splitt M, Superti-Furga A, Unger S, Williams D, Munnich A, Cormier-Daire V. 2011. Molecular screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of geleophysic dysplasia. J Med Genet 48:417-421.
2. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGFbeta activation. J Cell Sci 116:217-224.
3. Baldridge D, Shchelochkov O, Kelley B, Lee B. 2010. Signaling pathways in human skeletal dysplasias. Annu Rev Genomics Hum Genet 11:189-217.
4. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. 2008. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358:2787-2795.
5. Burglen L, He;ron D, Moerman A, Dieux-Coeslier A, Bourguignon JP, Bachy A, Carel JC, Cormier-Daire V, Manouvrier S, Verloes A. 2003. Myhre syndrome: New reports, review, and differential diagnosis. J Med Genet 40:546-551.
6. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. 2007. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 176:355-367.
7. Dagoneau N, Benoist-Lasselin C, Huber C, Faivre L, Megarbane A, Alswaid A, Dollfus H, Alembik Y, Munnich A, Legeai-Mallet L, Cormier-Daire V. 2004. ADAMTS 10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet 75:801-806.
8. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, et al. 1991. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352:337-339.
9. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. 1995. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270:10618-10624.
10. Faivre L, Le Merrer M, Baumann C, Polak M, Chatelain P, Sulmont V, Cousin J, Bost M, Cordier MP, Zackai E, Russell K, Finidori G, Pouliquen JC, Munnich A, Maroteaux P, Cormier-Daire V. 2001. Acromicric dysplasia: Long term outcome and evidence of autosomal dominant inheritance. J Med Genet 38:745-749.
11. Faivre L, Gorlin RJ, Wirtz MW, Godfrey M, Dagoneau N, Samples JR, Le Merrer M, Collod-Beroud G, Boileau C, Munnich A, Cormier-Daire V. 2003a. In-frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet 240:34-36.
12. Faivre L, Dollfus H, Lyonnet S, Alembik Y, Megarbane A, Samples J, Gorlin RJ, Alswaid A, Feingold J, Le Merrer M, Munnich A, Cormier-Daire V. 2003b. Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome. Am J Med Genet 123:204-207.
13. Feng XH, Derynck R. 2005. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 21:659-693.
14. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117-121.
15. Howe JR, Roth S, Ringold JC, Summers RW, Järvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. 1998. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280:1086-1088.
16. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278:2750-2757.
17. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, Guañabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melançon S, Cundy T, Van Hul W. 2006. Camurati-Engelmann disease: Review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 43:1-11.
18. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K. 2000. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 26:19-20.
19. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. 1998. The oncoprotein Evi-1 repress TGFbeta signaling by inhibiting Smad3. Nature 394:92-96.
20. Kutz WE, Wang LW, Bader HL, Majors AK, Iwata K, Traboulsi EI, Sakai LY, Keene DR, Apte SS. 2011. ADAMTS10 protein interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. J Biol Chem 286:17156-17167.
21. Le Goff C, Cormier-Daire V. 2009. Genetic and molecular aspects of acromelic dysplasia. Pediatr Endocrinol Rev 6:418-423.
22. Le Goff C, Morice-Picard F, Dagoneau N, Wang LW, Perrot C, Crow YJ, Bauer F, Flori E, Prost-Squarcioni C, Krakow D, Ge G, Greenspan DS, Bonnet D, Le Merrer M, Munnich A, Apte SS, Cormier-Daire V. 2008. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet 40:1119-1123.
23. Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, Jensen S, Zylberberg L, Collod-Beroud G, Bonnet D, Alanay Y, Brady AF, Cordier MP, Devriendt K, Genevieve D, Kiper PÖ, Kitoh H, Krakow D, Lynch SA, Le Merrer M, Me;garbane A, Mortier G, Odent S, Polak M, Rohrbach M, Sillence D, Stolte-Dijkstra I, Superti-Furga A, Rimoin DL, Topouchian V, Unger S, Zabel B, Bole-Feysot C, Nitschke P, Handford P, Casanova JL, Boileau C, Apte SS, Munnich A, Cormier-Daire V. 2011a. Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet 89:7-14.
24. Le Goff C, Mahaut C, Abhyankar A, Le Goff W, Serre V, Afenjar A, Destre;e A, di Rocco M, He;ron D, Jacquemont S, Marlin S, Simon M, Tolmie J, Verloes A, Casanova JL, Munnich A, Cormier-Daire V. 2011b. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet 44:85-88.
25. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. 2005. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37:275-281.
26. Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC. 2010. Mutations in fibrillin-1 cause congenital scleroderma: Stiff skin syndrome. Sci Transl Med 2:23ra20.
27. Marchesani O. 1939. Brachydaktylie und angeborene Kugellinse als Systemerkrankung Klin. Mibl Augenheilk 103:392-406.
28. Maroteaux P, Stanescu R, Stanescu V, Rappaport R. 1986. Acromicric dysplasia. Am J Med Genet 24:447-459.
29. Massague; J, Gomis RR. 2006. The logic of TGFbeta signalling. FEBS Lett 580:2811-2820.
30. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C, Kajii T, Jondeau G, Ohta T, Kishino T, Furukawa Y, Nakamura Y, Niikawa N, Boileau C, Matsumoto N. 2004. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855-860.
31. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T. 2009. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4:e5275.
32. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407-411.
33. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. 2004. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114:1586-1592.
34. Putnam EA, Zhang H, Ramirez F, Milewicz DM. 1995. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet 11:456-458.
35. Rahimi RA, Leof EB. 2007. TGFb signaling: A tale of two responses. J Cell Biochem 102:593-608.
36. Saharinen J, Keski-Oja J. 2000. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 11:2691-2704.
37. Sengle G, Tsutsui K, Keene DR, Tufa SF, Carlson EJ, Charbonneau NL, Ono RN, Sasaki T, Wirtz MK, Samples JR, Fessler LI, Fessler JH, Sekiguchi K, Hayflick SJ, Sakai LY. 2012. Microenvironmental regulation by fibrillin-1. PLoS Genet 8:e1002425.
38. Sheppard D. 2005. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev 24:395-402.
39. Shi Y, Massague J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.
40. Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA. 1996. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6:300-313.
41. Spranger JW, Gilbert EF, Tuffli GA, Rossiter FP, Opitz JM. 1971. Geleophysic dwarfism-A "focal" mucopolysaccharidosis? Lancet 10:97-98.
42. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X. 2009. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757-765.
43. ten Dijke P, Arthur HM. 2007. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8:857-869.
44. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, Vriend G, Pattynama PM, Colle;e M, Majoor-Krakauer D, Poldermans D, Frohn-Mulder IM, Micha D, Timmermans J, Hilhorst-Hofstee Y, Bierma-Zeinstra SM, Willems PJ, Kros JM, Oei EH, Oostra BA, Wessels MW, Bertoli-Avella AM. 2011. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 43:121-126.
45. Weill G. 1932. Ectopie du cristallin et malformations ge;ne;rales. Ann Occul 169:21-44.
46. Xu J, Attisano L. 2000. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci 97:4820-4825.